The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level
Open accessAbstract
The emergence of highly contagious influenza A virus strains, such as the new H1N1 swine influenza, represents a serious threat to global human health. Efforts to control emerging influenza strains focus on surveillance and early diagnosis, as well as development of effective vaccines and novel antiviral drugs. Herein we document the anti-influenza activity of the anti-infective drug nitazoxanide and its active circulating-metabolite tizoxanide and describe a class of second generation thiazolides effective against influenza A virus. Thiazolides inhibit the replication of H1N1 and different other strains of influenza A virus by a novel mechanism: they act at post-translational level by selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to endoglycosidase H digestion, thus impairing hemagglutinin intracellular trafficking and insertion into the host plasma membrane, a key step for correct assembly and exit of the virus from the host cell. Targeting the maturation of the viral glycoprotein offers the opportunity to disrupt the production of infectious viral particles attacking the pathogen at a level different from the currently available anti-influenza drugs. The results indicate that thiazolides may represent a new class of antiviral drugs effective against influenza A infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheung, C., Poon, L., Lau, A., Luk, W., Lau, Y., Shortridge, K., Gordon, S., Guan, Y., & Peiris, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11772-7 · Cited by 889
Cited by
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, J.-F. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.014 · Cited by 556
Self-citationContinuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Boldescu, V., Behnam, M. A. M., Vasilakis, N., & Klein, C. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.33 · Cited by 305
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Rossignol, J.-F. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.04.001 · Cited by 290
Self-citationPizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
“Interestingly, the proposed mode of action of nitazoxanide toward influenza is clearly distinct to that for which it was designed in its initial indication, acting at the post-translational level by selectively blocking the maturation of the viral glycoprotein HA, with a consecutive impact on its intracellular traffic…”
Background
Metadata
- Authors
- Rossignol, J. F., La Frazia, S., Chiappa, L., Ciucci, A., & Santoro, M. G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 284
- Issue
- 43
- Pages
- 29798-29808
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088399547
- Cited by
- 232
- References
- 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level. https://app.cochat.ai/papers/10.1074/jbc.m109.029470
- The paper
- Rossignol, J. F., La Frazia, S., Chiappa, L., Ciucci, A., & Santoro, M. G. (2009). Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m109.029470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.